Why a research opportunity mattered
Now to Love New Zealand reported that further drug treatment had not delivered the hoped-for result. Another patient told Walker about a particular CAR-T trial in China. After acceptance, she arrived in Shanghai in August 2025. The report also describes a substantial financial burden; access and affordability were both part of her decision.
A reported response, with an open future
Walker described fevers after infusion and a marked fall in her myeloma markers. By the April 2026 interview, she reported deep remission and had returned to tennis and walking. The article records that point in her recovery, without establishing how long the response would last.
China Care perspective
What this case helps us understand
A research programme became part of Walker’s search for more time with her family. This illustrates how medical capability includes organised clinical research and the ability to assess patients for a specific protocol. The financial context belongs in the story because she described it herself. The medical distinction is the trial opportunity she ultimately entered, with its own eligibility criteria and unresolved questions.
Sources & further reading
Original reporting belongs to the publishers below. This article is an independently written account based on those sources, with editorial interpretation identified above.
- Now to Love New ZealandJulie Walker shares her life-saving treatment in China (opens in a new tab)
Interview by Kasia De Vydt-Jillings; relapse, trial participation and patient-reported recovery
China Care did not provide the care described. This story does not imply a relationship with the patient or hospital, or that China Care can arrange the same treatment. Individual outcomes do not predict other patients’ results. This is editorial information, not medical advice.
Published by China Care on 29 October 2026. Patient experiences and treatment access reflect the dates of the cited reporting.